Drugs / PN400
last change Feb 2019 re-read 2 minutes ago

PN400

also known as VIMOVO
Developed for
juvenile idiopathic arthritis
Investigated by
AstraZeneca · Amgen

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) VIMOVO 2010-04-30 fda.gov

Trials 3 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00907400 May → Sep 2009 AstraZeneca Completed No outcome recorded
Phase 1 NCT00761501 Sep → Dec 2008 AstraZeneca Completed No outcome recorded
Phase 41 trial
Phase 4 NCT01544114 Apr 2012 → Feb 2015 juvenile idiopathic arthritis Amgen Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02604446 Background Sep 2015 → Feb 2019 arthritic joint disease St. Olavs Hospital Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as PN400 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00907400
1

NCT00761501

Known as VIMOVO “premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo” NCT02604446
1

NCT01544114

Route Oral oral tablet” NCT00907400